Stock GRI GRI BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GRI Bio, Inc.

Equities

GRI

US3622AW3040

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 03:30:00 02/07/2024 am IST 		5-day change 1st Jan Change
1.64 USD -13.68% Intraday chart for GRI Bio, Inc. -10.38% -95.32%
02/07 GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine CI
21/05 GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus CI

Valuation

Fiscal Period: December 2023
Capitalization 1 1.74
Enterprise Value (EV) 1 -0.054
P/E ratio -0.1 x
Yield -
Capitalization / Revenue -
EV / Revenue -
EV / EBITDA 0 x
EV / FCF 10,386 x
FCF Yield 0.01%
Price to Book 6.72 x
Nbr of stocks (in thousands) 49.7
Reference price 2 35.03
Announcement Date 28/03/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - - -
EBITDA 1 -1.456 -1.059 -2.236 -11.13
EBIT 1 -1.459 -1.062 -2.239 -11.14
Operating Margin - - - -
Earnings before Tax (EBT) 1 -2.531 -1.559 -3.217 -13.04
Net income 1 -2.531 -1.559 -3.217 -13.04
Net margin - - - -
EPS 2 -9.860 -5.940 -12.13 -367.2
Free Cash Flow - -1.609 -1.804 -5.196
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 23/12/22 23/12/22 24/02/23 28/03/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 2.72 3.52 0.66 -
Net Cash position 1 - - - 1.79
Leverage (Debt/EBITDA) -1.87 x -3.328 x -0.297 x -
Free Cash Flow - -1.61 -1.8 -5.2
ROE (net income / shareholders' equity) - 31.8% 99.4% 1,909%
ROA (Net income/ Total Assets) - -227% -466% -417%
Assets 1 - 0.6882 0.6908 3.127
Book Value Per Share 2 -19.30 -0.2100 -0.0600 5.210
Cash Flow per Share 2 1.310 0 0 36.40
Capex - - 0 0.01
Capex / Sales - - - -
Announcement Date 23/12/22 23/12/22 24/02/23 28/03/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GRI BIO, INC. Stock GRI Bio, Inc.
-95.32% 5L
MODERNA, INC. Stock Moderna, Inc.
+16.59% 4.49TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 3.78TCr
LONZA GROUP AG Stock Lonza Group AG
+40.49% 3.76TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 3.13TCr
CELLTRION, INC. Stock Celltrion, Inc.
-9.78% 2.74TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 2.63TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 1.41TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 1.25TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 1.12TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GRI Stock
  4. Financials GRI Bio, Inc.